US FDA working to make clinical trials less wasteful

By Zachary Brennan contact

- Last updated on GMT

Related tags: Good clinical practice, Clinical trial

FDA looks to cut back on the waste from having to start trials from scratch
FDA looks to cut back on the waste from having to start trials from scratch
The US FDA is looking to set up master protocols that can continuously run and help cut down on waste that’s prevalent in the clinical trial industry, Director of FDA's Center for Drug Evaluation and Research Janet Woodcock said in an interview.

Sponsors often set up a global trial that they run with different investigators “and then when the trial's done, they shut all that infrastructure down, and if you need another trial, it all starts up again, and so that wastes a lot of time, a lot of resources​,” Woodcock said. “We have tried and are working on several master protocols that continuously run and can evaluate numerous investigational products at once, and many over time, because the trial doesn't shut down​.” 

With vision and with persistence, we could develop a better trial system that could effectively and quickly evaluate therapies and really evaluate them dispassionately​,” Woodcock said.

The agency is also working through the Clinical Trials Transformation Initiative (CTTI) “to bite off different pieces of the current trial conduct and design and re-design those, and I think we've made significant progress there​,” Woodcock said.

The CTTI was established by Duke University and the FDA as a public-private partnership in 2007, and now comprises more than 60 member organizations working to identify and promote practices that will increase the quality and efficiency of clinical trials. Most recently the initiative unveiled recommendations​ to streamline Good Clinical Practice (GCP) training of investigators who participate in clinical trials.

Trial Funding Ethics

Woodcock also noted that another problem with trials, “at least in many people's mind, is that they are funded by the sponsor and conducted by people the sponsor pays​.”

She calls instead for a more independent and non-biased way to conduct the trial and assess the data.

With master protocol-type designs, Woodcock said, “you have a trialist group, and they take money from many sponsors to evaluate their product, but they're more or less independent, because they're evaluating many different products, and this, to me, gives one degree of separation that would give a lot of people comfort about how…the data was generated and could be interpreted and relied upon​.”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars